[Metformin--new treatment strategies for gynecologic neoplasms]
- PMID: 23879009
[Metformin--new treatment strategies for gynecologic neoplasms]
Abstract
Metformin, a drug from the biguanide class, is now one of the most widely used drugs in the treatment of type 2 diabetes. This drug was also used in the treatment of polycystic ovarian syndrome and recent reports indicate the possibility of using this drug in oncology. Latest findings show that metformin has an anticancer effect. Influencing the transduction mechanisms primarily through activation of protein kinase activated by 5'AMP (AMPK) regulates the activity of the AMPK/mTOR signaling pathway. MTOR pathway dysregulation may be a factor in the pathogenesis of various human diseases, especially cancers. Overactivation of mTOR is observed in malignant cells and is associated with their resistance to treatment. It can therefore be concluded that metformin as an inhibitor of mTOR may be a factor that suppresses tumor development. There are also studies showing that metformin prevents the formation of metastases, reducing tumor vasculature and improves the effectiveness of anticancer drugs. The anticancer effect of metformin has been proven in the treatment of colorectal and breast cancer. The current studies reports the positive effects in the treatment of gynecological cancers such as ovarian, endometrial and cervical cancer. Incidence for these tumors in 2009 in Poland was: for ovarian cancer 11.01100000; for endometrial cancer 15.0/100000; for cervical cancer 10.5/100000. Metformin has antitumor activity in monotherapy and also synergistically with other anticancer agents. Metformin has antiproliferative properties; reduces the VEGF levels, causing a reduction in tumor vasculature; causes an increase in progesterone receptor, which increases the response to hormonal therapy; inhibits the expression of glyoxalase I, mediating resistance to chemotherapy; decreases in the concentration of human telomerase; reduces the activity of Akt and Erk kinases, key regulators of metabolism and progression of tumors and also inhibits the formation of metastases.
Similar articles
-
Metformin: taking away the candy for cancer?Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Eur J Cancer. 2010. PMID: 20656475 Review.
-
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.Cancer Treat Rev. 2012 Oct;38(6):767-75. doi: 10.1016/j.ctrv.2012.02.001. Epub 2012 Feb 29. Cancer Treat Rev. 2012. PMID: 22381585 Review.
-
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4. Clin Cancer Res. 2011. PMID: 21543517
-
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):113-20. doi: 10.1016/j.jsbmb.2010.12.006. Epub 2010 Dec 17. J Steroid Biochem Mol Biol. 2011. PMID: 21168492
-
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.Anticancer Res. 2012 May;32(5):1627-37. Anticancer Res. 2012. PMID: 22593441
Cited by
-
Metformin Regulates TET2 Expression to Inhibit Endometrial Carcinoma Proliferation: A New Mechanism.Front Oncol. 2022 Apr 11;12:856707. doi: 10.3389/fonc.2022.856707. eCollection 2022. Front Oncol. 2022. PMID: 35480097 Free PMC article.
-
Effect of metformin on apoptosis induction in ovarian cancer cells.Prz Menopauzalny. 2014 Jun;13(3):155-61. doi: 10.5114/pm.2014.43817. Epub 2014 Jun 29. Prz Menopauzalny. 2014. PMID: 26327848 Free PMC article.
-
Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation.Int J Oncol. 2018 Jun;52(6):1899-1911. doi: 10.3892/ijo.2018.4343. Epub 2018 Mar 29. Int J Oncol. 2018. PMID: 29620187 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous